CJC-1295 + Ipamorelin: Growth Hormone Research Compared

CJC-1295: the controlled human evidence

Teichman and colleagues conducted two randomised, placebo-controlled, double-blind studies of the long-acting GHRH analogue CJC-1295 in healthy adults. They measured pharmacokinetics and GH/IGF-I responses over study periods of 28 and 49 days. The estimated half-life was 5.8–8.1 days. Read the primary study.

These studies establish that the compound was studied in humans and changed measured hormone levels. They do not test a catalogue blend with ipamorelin or establish long-term body-composition, recovery or longevity benefits for that pair. The short observation periods also limit the safety conclusions.

DAC and non-DAC names are not interchangeable

The CJC-1295 studied by Teichman et al. was a long-acting GHRH analogue. Products described as CJC-1295 without DAC or modified GRF (1-29) should not inherit that study’s half-life or exposure findings solely because their names are similar.

Match the structure, formulation and exposure profile to the material in the paper. For the wider comparison, see CJC-1295, ipamorelin and sermorelin.

Ipamorelin: what the selectivity paper tested

Raun and colleagues characterised ipamorelin as a pentapeptide GH secretagogue using rat pituitary cells, rats and swine. Their selectivity findings included comparisons of GH and other hormone responses in those experimental systems. Read the 1998 primary study.

An animal hormone-response comparison does not establish that human users will experience no appetite changes or other effects. It also does not test CJC-1295/ipamorelin combination outcomes. Keep the reported selectivity attached to its experimental model.

A separate 1999 study measured ipamorelin pharmacokinetics and GH responses after intravenous infusion in healthy male volunteers, with eight participants at each of five dose levels. The estimated terminal half-life was about two hours. This is human evidence for that route and endpoint, not a CJC-1295 combination study or a subcutaneous catalogue-product regimen. Read the human pharmacokinetic study.

Two pathways do not prove a synergistic stack

GHRH signalling and growth-hormone secretagogue signalling provide distinct starting points for an experimental comparison. The studies cited here test the individual compounds, so this page does not assign an amplification factor to their combination.

A combined response would need to be measured against matched individual-compound controls with the same endpoints and observation window. Distinguish a change in GH or IGF-I from a demonstrated change in tissue, physical performance or body composition.

Choosing a research material by the question

A clinical study’s dosing design describes that trial; it is not a personal regimen or an instruction for using research reagents. For laboratory handling, follow the material-specific documentation and the approved protocol. Use batch reports to check analytical evidence before comparing products.

Conclusion

The strongest distinction is between controlled evidence for CJC-1295 alone, model-specific ipamorelin findings and a proposed combination experiment. Select a defined material and measurable endpoint; neither receptor rationale nor a short-term hormone response validates a commercial stack’s claimed recovery or longevity benefits.